

**RESOLUTION NO. 20080925-080**

**WHEREAS,** *medical research aids in improving prevention and treatment of illness and is necessary for Level I Trauma Center status, and*

**WHEREAS,** *medical research initiatives can help build the foundation for a medical school in Austin; and*

**WHEREAS,** *University Medical Center Brackenridge (UMCB) is currently a Level II Trauma Center and has more than 200 research initiatives underway, and*

**WHEREAS,** *Emergency Service Partners, LP, and UMCB are currently seeking community consent for UMCB to participate in a double-blind randomized clinical trial known as the Rapid Anticonvulsant Medication Prior to Arrival Trial (RAMPART) which will compare the efficacy of intramuscular midazolam (Versed) versus intravenous lorazepam (Ativan) when used by paramedics in the pre-hospital treatment of seizures; and*


**WHEREAS,** *emergency medical services patients having seizures (status epilepticus) require immediate treatment and these patients cannot provide informed consent, and*

**WHEREAS**, community consent is part of the process required by an institutional review board before UMCB can initiate study in patients who cannot grant informed consent prior to initiation of treatment; **NOW, THEREFORE,**

**BE IT RESOLVED BY THE CITY COUNCIL OF THE CITY OF AUSTIN:**

Upon the recommendation of the City Council's Public Health and Human Services Committee, the City Council, as part of the community consent process, endorses the participation of UMCB in the RAMPART clinical trial to help achieve the following benefits to the community: better and faster treatment of epilepsy cases; paramedics who are better equipped and educated in handling epilepsy and contribution by our medical community to the "best practices" understanding of medicine.

**ADOPTED:** September 25, 2008

**ATTEST:**   
Shirley A. Gentry  
City Clerk